Table 1.
Patient and tumor characteristics
| Survivors | Non-survivors | NA* | ||
| (n = 60) | (n = 23) | (n = 2) | ||
| Mean age (± SD) | years | 51.1 ± 10.6 | 49.3 ± 8.3 | 46.4 ± 2.6 |
| Mean tumor dimensions (mean ± SD) | mm | 67.9 × 67.9 ± 18.0 × 19.8 | 78.6 × 77.3 ± 22.0 × 24.0 | 65.0 × 51.5 ± 7.1 × 26.2 |
| NAC treatment | Epirubicin | 25 | 8 | - |
| Paclitaxel | 23 | 5 | 2 | |
| Both1 | 12 | 10 | - | |
| Treatment | Partial response | 40 | 11 | 1 |
| response | Stable disease | 20 | 12 | 1 |
| AJCC | IIB | 21 | 7 | 1 |
| IIIA | 25 | 11 | 1 | |
| IIIB | 12 | 2 | - | |
| IV | 2 | 3 | - | |
| ER status | + | 41 | 7 | 2 |
| - | 19 | 15 | - | |
| unknown | - | 1 | - | |
| PgR status | + | 32 | 14 | 2 |
| - | 28 | 18 | - | |
| unknown | - | 1 | - | |
| Nodes | + | 32 | 14 | 1 |
| - | 28 | 9 | 1 | |
| Metastasis | + | 2 | 2 | 0 |
| - | 58 | 21 | 2 |
*NA, not applicable--One patient without following up and one patient dead by other causes; AJCC, American Joint Committee on Cancer; Both1, sequential treatment with Epirubicin and Paclitaxel